EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective

Lei He, Da Zhang, Eric J Gapud, Suzette Peng, Ozlem Belen, Chandrahas Sahajwalla, Suresh Doddapaneni, Youwei Bi, Jianmeng Chen

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70104 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Lei He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and R…. Hauptthemen laut MEDLINE: Arthritis, Juvenile, Arthritis, Psoriatic, Heterocyclic Compounds, 3-Ring, Antirheumatic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

On April 26, 2024, FDA approved Rinvoq (upadacitinib, extended‐release [ER] tablets) and Rinvoq LQ (1 mg/mL oral solution), a new pediatric immediate‐release (IR) formulation, for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) and active psoriatic arthritis (PsA) in patients 2 years of age and older. The approved dosing regimens include a weight‐tiered twice daily (BID) regimen with IR oral solution and a once‐daily (QD) regimen with ER tablets. The objective of this article is to summarize the FDA's major review findings and considerations supporting these approvals from a regulatory perspective. This clinical development program included a single study (Study 1) conducted in pediatric subjects aged 2 to less than 18 years with JIA with active polyarthritis to evaluate the pharmacokinetics (PK), safety, and tolerability of multiple doses of upadacitinib. No clinical trials or dedicated PK studies were conducted in pediatric patients with PsA. Efficacy was extrapolated from adults with rheumatoid arthritis (RA) or PsA to pediatric patients with pJIA or PsA, respectively, based on a PK‐matching approach considering disease similarity, similar response to treatment, and comparable PK exposure. PK data analysis and simulations showed that the approved upadacitinib pediatric dosing regimen, including a BID regimen with IR oral solution and QD regimen with ER tablet, provide comparable PK exposure (Cmax and AUC) in pediatric subjects with pJIA or PsA as compared to the approved 15 mg ER tablet QD regimen in adults with RA or PsA, respectively, supporting the efficacy extrapolation from adults to pediatric subjects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, JuvenileArthritis, PsoriaticHeterocyclic Compounds, 3-RingAntirheumatic AgentsHumansChildDrug ApprovalAdolescentUnited StatesUnited States Food and Drug AdministrationChild, PreschoolDelayed-Action PreparationsMale

Stichwörter der Autor:innen

PK matchingdosing intervalefficacy extrapolationpJIApediatric PsAregulatory perspective

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingAntirheumatic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Division of Pharmacometrics, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
  • Division of Rheumatology and Transplant Medicine, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

Förderung

  • Intramural FDA HHS

Zitieren

APA

He, L., Zhang, D., Gapud, E. J., Peng, S., Belen, O., Sahajwalla, C., Doddapaneni, S., Bi, Y., & Chen, J. (2026). Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70104

Vancouver

He L, Zhang D, Gapud EJ, Peng S, Belen O, Sahajwalla C, et al. Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70104

BibTeX
@article{He2026,
  author = {He, Lei and Zhang, Da and Gapud, Eric J and Peng, Suzette and Belen, Ozlem and Sahajwalla, Chandrahas and Doddapaneni, Suresh and Bi, Youwei and Chen, Jianmeng},
  title = {Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70104}
}
Kostenlos starten →